Beleggen.nl Markt MonitorMarkt Monitor

Sopheon Terug naar discussie overzicht

Sopheon maart 2021

55 Posts
Pagina: «« 1 2 3 »» | Laatste | Omlaag ↓
  1. Gartje 4 maart 2021 19:28
    Ik ben wat voorzichtiger, en eerst maar weer eens door die 10 pond heen komen. Wat wel duidelijk is natuurlijk dat veel grote beleggings maatschappijen vertrouwen hebben in Sopheon, anders koop je geen aandelen aan. Dus op naar 23 Maart met hopenlijk een mooie outlook voor 2021.
  2. Bertus S 4 maart 2021 20:17
    quote:

    Gartje schreef op 4 maart 2021 19:28:

    Wat wel duidelijk is natuurlijk dat veel grote beleggingsmaatschappijen vertrouwen hebben in Sopheon, anders koop je geen aandelen aan.
    Hoor ik daar "een kwartje" vallen??

    *_*

    Bertus S.
  3. Gartje 12 maart 2021 11:19
    Geen beweging in te krijgen, maar wel terug van 10 pond naar 8,60. Gelukkig hebben we de drank nog;-))
  4. Gartje 17 maart 2021 09:59
    Wie trekt er even aan de bel bij Sopheon! Lijkt wel of dat ze in slaap zijn gevallen. Een freeze waar je als aandeelhouder niet op zit te wachten!
  5. [verwijderd] 24 maart 2021 08:28
    Zoals jullie weten ,heb ik het geluk gehad om al mijn aandelen in Sopheon te verkopen rond hun ATH. Op dat moment vond ik the K/W verhouding niet meer in verhouding staan t.o.v hun groei!
    Ben ook Noot meer ingestapt ook niet op 5,
    Mijn mening is dat Sopheon een goed bedrijf is, aangezien the omstandigheden van, zeg de laatste 15 maanden.. Ze maken ongeveer de zelfde winst als vorige jaar.( Cijfers zijn net uit) Maar het dividend rendement is te laag om in te stappen.
    Naar mijn mening doen ze te weinig met hun excellent gevulde kas! Dus in mijn ogen zijn er 1 reden om weer in te stappen, als ze een overname doen wat de groei weer aanzwengelt. Aangezien ik dit al jaren verwachtt en gebeurt niet , daarbij de aandelen verkoop op 9 euro doen mij niet hoopgevend stemmen.
    Het beste voor de huidige aandeelhouders zou een overname zijn! Maar dan ben ik te laat!

    Conclusie voor mij; dood geld voor te time being en alleen een overname door Sopheon zou mijn interesse weer wekken.
    Voor jullie een overname van Sopheon.

    Suc6 allemaal .

    Groet trinko
  6. Bertus S 24 maart 2021 09:01
    Hier nog even de samenvatting:

    Audited Results Statement for the Year to 31 December 2020

    Sopheon plc, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, is pleased to announce its results for the year ended 31 December 2020, in line with market expectations, together with an outlook for the current year.

    Financial Highlights:

    Revenue of $30.0m, maintained in the face of challenging year due to COVID, whilst embarking on a SaaS transition (2019: $30.3m)
    ARR1 rose from $15.9m at the start of 2020 to $18.0m at the end of the year
    Full year 2021 revenue visibility2 is now at $24.5m (last year at this time: $21.2m)
    TCV2 of signed contract bookings up 1.25X, and TCV of SaaS bookings up 2.74X
    Adjusted EBITDA3 of $5.9m (2019: $6.4m)
    PBT of $1.7m (2019: $2.5m)
    Net cash of $21.7m (2019: $19.4m) and the Group has no debt
    Dividend to be maintained at 3.25p per share (2019: 3.25p)

    Operational Highlights

    10 new customer wins including DuPont, LG, Hochland, Clif Bar and Mondelez. Six of the new customers signed had deal values over $1m.
    SaaS First and SaaS uplift programs introduced to assist clients in moving to the cloud. Over 50% of new clients signed SaaS contracts and four existing clients converted to SaaS as part of the SaaS Uplift program.
    Continued investment in cloud-native SaaS capabilities for Accolade
    Gross retention of 91.5% (2019: 94.2%) with customers taking cost decisions earlier in the year, with a return to improved levels in the second half
    Greg Coticchia, who has been working with us for some time and demonstrated his capability and value add to the Group, to join Board and spearhead cloud strategy as CEO. Andy Michuda to become Executive Chairman, focusing on partnerships and M&A alongside governance. Barry Mence to step down to become a Non-Executive Director.

    Barry Mence, Chairman, commented: “With a solid revenue base already in place for 2021, plus our strong balance sheet, a superb customer base and a team of great people – I am confident that Sopheon has a great future, and that the SaaS transition is exactly the right strategy to pursue. The board is excited to be appointing Greg Coticchia as CEO – he is already having significant impact on the business, and his experience and track record in software and innovation are invaluable. I can think of no better person than Andy Michuda for the role of Executive Chairman. My own commitment to Sopheon is undimmed, and I will remain a non-executive director and major shareholder in the company as we go through this exciting new chapter in the Sopheon story. We also continue to believe in sharing success with shareholders, and I am therefore pleased to announce that we will again maintain our dividend at 3.25p per share.”

    For further information contact:

    Barry Mence (Chairman)
    Arif Karimjee (CFO) Sopheon plc + 44 (0) 1276 919 560

    Bertus S.
  7. Gartje 24 maart 2021 09:50
    Eens abc, maar als ik Mence lees dan wil hij wat terug doen voor de aandeelhouders, met zijn 3:25 per aandeel, gezien zijn greep in de kas had 5 pence een goed signaal geweest naar de toekomst en de cijfers voor 2021 voor de trouwe aandeelhouders!!
  8. [verwijderd] 24 maart 2021 11:33
    quote:

    abc123xyz987 schreef op 24 maart 2021 09:19:

    Paniekjaar 2020 zo afsluiten + hoogste visibility ooit. Ik vind het knap.

    Groet ABC.
    eens, dividend na zn wereldwijde pandemie die nog heerst, en hochland is ook geen klein klantje.
  9. [verwijderd] 24 maart 2021 15:08
    Sopheon Names Greg Coticchia Chief Executive Officer
    Experienced Tech Leader to Drive Growth of Sopheon’s SaaS-based Enterprise Innovation Management Platform

    MINNEAPOLIS –March 24, 2021 – Sopheon (LSE: SPE) today announced the appointment of Greg Coticchia to the position of Chief Executive Officer (CEO), effective on March 31, 2021. As part of this planned transition strategy, Andy Michuda will become Executive Chairman of Sopheon’s Board of Directors. Barry Mence, who has been Chairman of the Board since the company’s inception, will serve as a non-executive director of Sopheon and remain a major investor in the company.

    Coticchia, who joined Sopheon as President in 2020, will also take a seat on the board of directors. With deep experience in the creation and growth of SaaS companies, Coticchia is an award-winning entrepreneur, business strategist, product manager and marketing expert.

    Coticchia will spearhead Sopheon’s growth as the industry’s most versatile and powerful enterprise innovation management cloud platform. Michuda will focus on partnerships and acquisitions, in addition to his governance responsibilities as Executive Chairman.

    “Digital transformation continues to accelerate, and innovation is an urgent imperative for virtually every company,” said Coticchia. “But fostering and governing innovation can be difficult in large organizations with diverse methodologies and siloed teams. Sopheon has a large opportunity to build upon its success at hundreds of companies worldwide to drive— and keep—innovation moving forward aggressively while still delivering resilient and reliable product experiences."

    “We welcome Greg to Sopheon’s board of directors and look forward to his creative and energetic leadership as CEO,” said Mence, a co-founder of Sopheon. “Greg is a highly-regarded entrepreneur, business leader, professor and author. His impressive experience in leading strategic transitions in the SaaS industry is an ideal fit as we continue to grow our popular SaaS-based offerings.”

    Accolade is Sopheon’s innovation management platform. Accolade enables businesses to operate with more agility and responsiveness. By creating cross-functional collaboration and synchronization, Accolade connects people, systems and information across departments and functions. This results in faster time to market, increased product success and reduced costs.

    Accolade has proven its value to thousands of global users, such as PepsiCo, P&G, Merck KgaA, Mondelez, BASF, Parker Hannifin and other innovation and market leaders across a wide variety of industries.

    For more information about how Sopheon is transforming enterprise innovation, visit our website at www.sopheon.com.

    Sopheon released financial results for 2020 earlier today. The annual report can be viewed at www.sopheon.com/financial-reports.
55 Posts
Pagina: «« 1 2 3 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 6.998
AB InBev 2 5.479
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.146
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.470
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.625
Aedifica 3 900
Aegon 3.258 322.619
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.884
Agfa-Gevaert 14 2.047
Ahold 3.538 74.288
Air France - KLM 1.025 34.975
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.031
Alfen 16 24.260
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 403
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.811
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.834 242.612
AMG 971 133.006
AMS 3 73
Amsterdam Commodities 305 6.685
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 481
Antonov 22.632 153.605
Aperam 92 14.886
Apollo Alternative Assets 1 17
Apple 5 379
Arcadis 252 8.731
Arcelor Mittal 2.033 320.460
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.282
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.067
ASML 1.766 105.569
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 466
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.584
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.385